Horizon Discovery EGFR Multiplex cfDNA Reference Standard

Horizon Discovery has launched a new cell line-derived EGFR Multiplex cell-free DNA reference standard, which allows labs and assay developers to optimize, validate and routinely monitor performance of PCR assays, NGS tests, and other novel liquid biopsy tests designed to detect EGFR mutations in cfDNA.

The new referene standard covers ten of the most clinically relevant mutations that predict responsiveness to EGFR tyrosine kinase inhibitors, including T790M, L858R, C797S and E746-A750del. Additionally, variants have been carefully selected to represent a mix of different mutation types that can be challenging for laboratories to detect.